ArticleNPJ digital medicine2026
An agentic AI system for automated pharmacogenomic recommendation generation.
Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenomic guidelines are essential for tailoring drug therapy to individual genetic profiles, but current curation workflows are manual, resource‑intensive, time‑bound, and limited in coverage. We introduce an agentic AI system for automated, scalable generation of CPIC-style recommendations using large language models (LLMs) guided by structured evidence. Our modular pipeline retrieves and processes full-text biomedical literature and FDA drug labels, extracts clinically relevant entities with high accuracy (91.9% across 22 articles), aggregates findings across studies, and generates phenotype-specific dosing recommendations for gene-drug pairs. In expert evaluations of 24 random recommendations, our system significantly outperformed leading LLM baselines (GPT-5, Claude, Grok) in clinical clarity and guideline concordance. These results demonstrate the feasibility of using evidence-grounded, agentic AI for end-to-end pharmacogenomic evidence synthesis, offering a path toward broader population coverage, faster updates, and more consistent and explainable decision support.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.